

**Sun Pharmaceutical Industries Ltd.**

Sun House, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai - 400 063, Maharashtra, INDIA.  
Tel. : (91-22) 4324 4324  
Fax : (91-22) 4324 4343  
Website : www.sunpharma.com  
CIN : L24230GJ1993PLC019050



**6<sup>th</sup> December, 2019**

**National Stock Exchange of India Ltd.,**  
Exchange Plaza, 5th Floor,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (East), Mumbai – 400 051.  
**NSE Code: SUNPHARMA**

**BSE Limited,**  
Market Operations Dept.  
P. J. Towers,  
Dalal Street,  
Mumbai - 400 001.  
**Stock Code: 524715**

Dear Sirs,

**Sub: Intimation under Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the details of related party transactions on consolidated basis for the half year ended 30<sup>th</sup> September, 2019 in the format specified in the relevant accounting standards for annual results.

This is for your information and record.

Thanking you,

Yours faithfully,  
For **Sun Pharmaceutical Industries Ltd.**

**Ashok I. Bhuta**  
**Compliance Officer**

Encl: A/a

**SUN PHARMACEUTICAL INDUSTRIES LIMITED**

Related Party disclosure on a consolidated basis - Half year ended September 30, 2019

**Names of related parties where there are transactions and description of relationships**

**a Key Management Personnel (KMP)**

Dilip S. Shanghvi  
Sudhir V. Valia

Managing Director

Designation changed from Whole-time Director to  
Non-Executive and Non independent Director w.e.f.  
May 29, 2019

Sailesh T. Desai  
Israel Makov

Whole-time Director

Chairman and Non- Executive Director

Kalyanasundaram Subramanian

Whole-time Director

**b Relatives of Key Management Personnel**

Aalok Shanghvi  
Vidhi Shanghvi

**c Others (Entities in which the KMP and Relatives of KMP have control or significant influence)**

Makov Associates Ltd  
Sun Pharma Advanced Research Company Limited.  
Sun Petrochemicals Private Limited  
Alfa Infraprop Private Limited  
Sidmak Laboratories (India) Private Limited  
Ramdev Chemicals Private Limited (upto 25.04.2019)  
United Medisales Private Limited  
Aditya Medisales Limited  
Shanghvi Finance Private Limited  
Fortune Integrated Assets Finance Limited  
Suraksha Asset Reconstruction Private Limited

**d Joint Venture**

Artes Biotechnology GmbH

**e Associates**

Medinstill LLC  
Medinstill Development LLC  
Dr. Py Institute LLC

**f Unconsolidated Subsidiary**

Foundation for Disease Elimination and Control of India



SUN PHARMACEUTICAL INDUSTRIES LIMITED

Related Party disclosure on a consolidated basis - Half year ended September 30, 2019

Transactions during half year ended September 30, 2019 with related parties :

₹ In Million

	Half Year ended September 30, 2019
<b>Purchase of goods</b>	<b>53.8</b>
Others	53.8
<b>Revenue from contracts with customers, net of returns</b>	<b>9.2</b>
Others	9.2
<b>Sale of property, plant and equipment and other intangible assets</b>	<b>4.4</b>
Others	4.4
<b>Receiving of service</b>	<b>797.9</b>
Others	769.8
Joint venture	28.1
<b>Reimbursement of expenses - Paid</b>	<b>485.8</b>
Associate	13.7
Others	472.1
<b>Rendering of service</b>	<b>70.8</b>
Others	70.8
<b>Reimbursement of expenses - Received</b>	<b>271.8</b>
Others	271.8
<b>Loans / deposits given</b>	<b>63.0</b>
Associate	63.0
<b>Interest income</b>	<b>69.2</b>
Others	69.2
<b>Lease Rental and hire charges ( Income )</b>	<b>11.5</b>
Others	11.5
<b>Rent expense</b>	<b>3.9</b>
Others	3.9
<b>Remuneration/ compensation</b>	<b>226.1</b>
Key management personnel	209.6
Relatives of Key management personnel	16.5
<b>Donation</b>	<b>24.5</b>
Unconsolidated subsidiary	24.5

Key Management Personnel (KMP) and Relatives of KMP who are under the employment of the Company are entitled to post employment benefits and other long term employee benefits recognised as per Ind AS 19 - 'Employee Benefits'. As these employee benefits are lump sum amount provided on the basis of actuarial valuation, the same is not included above and there is no Share-based payments to key management personnel and relatives of KMP.

